Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies
| Autor: | Clive S. Zent, Paul M. Barr, Michelle C. Janelsins, Philip J. Meacham, AnnaLynn M. Williams, Megan M Feldman, Hugo E Valencia, Nealansh Gupta, Catherine Newsom-Stewart, Andrea Baran |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Chronic lymphocytic leukemia Communicable Diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Chemoimmunotherapy Risk Factors hemic and lymphatic diseases Internal medicine Medicine Humans In patient Molecular Targeted Therapy Chemotherapy business.industry Risk of infection Adenine Hematology Middle Aged Antimicrobial medicine.disease Prognosis Leukemia Lymphocytic Chronic B-Cell Pyrimidines Oncology chemistry 030220 oncology & carcinogenesis Ibrutinib Immunology population characteristics Pyrazoles Female business Risk assessment 030215 immunology Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 59(3) |
| ISSN: | 1029-2403 |
| Popis: | We studied the risk of infections in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Major infections were defined as requiring hospital admission or intravenous antimicrobial treatment. Incidence rate (IR) ratios (IRR) were used to compare infection rates. Of 263 CLL patients followed for 936.9 person-years, 60% required treatment for progressive CLL (66 received ibrutinib). Infections occurred in 71.9% patients (IR 92.4/100 person-years) with 31.9% having major infections (IR 20.3/100 person-years) and infections causing 37.5% of deaths. CLL treatment was associated with significantly higher risk of major (IRR 3.31, 95% CI 2.10, 5.21) and minor (IRR 1.78, 95% CI 1.43, 2.22) infections. Compared to their previous chemoimmunotherapy patients receiving salvage ibrutinib therapy (n = 47) had a significantly increased risk of a major infection (IRR 2.35 95% CI 1.27, 4.34). The risk of infection in CLL patients remains high even with use of less immunosuppressive therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|